Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol

Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol

Viking Therapeutics will present updated data from a 12-week Phase 2 study of VK2809 in patients with non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C) at the International Liver Congress™ 2019. The study results will...

Pin It on Pinterest